scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.CLGC.2018.01.019 |
P8608 | Fatcat ID | release_fazo77hpjff6tjss3sxhlk7toa |
P932 | PMC publication ID | 6136146 |
P698 | PubMed publication ID | 29534939 |
P50 | author | Ulka Vaishampayan | Q86981393 |
P2093 | author name string | Jing Li | |
Elisabeth Heath | |||
Karri Stark | |||
Joseph Fontana | |||
Daryn Smith | |||
Lance Heilbrun | |||
Julie Boerner | |||
Manish K Thakur | |||
Kimberlee Dobson | |||
P2860 | cites work | Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline | Q26852544 |
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Q28275476 | ||
Cancer statistics, 2016 | Q29547383 | ||
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer | Q30080026 | ||
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. | Q31156220 | ||
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
Aggressive variants of castration-resistant prostate cancer | Q33693256 | ||
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 | ||
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline | Q36778558 | ||
Pasireotide (SOM230): development, mechanism of action and potential applications | Q36989087 | ||
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets | Q39385550 | ||
Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide | Q39887659 | ||
The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts | Q40608819 | ||
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Q41082307 | ||
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study | Q44748178 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 | ||
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial | Q48322695 | ||
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer | Q57693338 | ||
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer | Q83831101 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | docetaxel | Q420436 |
phase I clinical trial | Q5452194 | ||
P304 | page(s) | e695-e703 | |
P577 | publication date | 2018-02-13 | |
P1433 | published in | Clinical Genitourinary Cancer | Q332266 |
P1476 | title | Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. | |
P478 | volume | 16 |
Q92440624 | Development of chimeric and bifunctional antagonists for CLR/RAMP receptors |
Q64266568 | Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells |
Q53682879 | The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. |
Search more.